222 related articles for article (PubMed ID: 35307752)
81. How Different Substitution Positions of F, Cl Atoms in Benzene Ring of 5-Methylpyrimidine Pyridine Derivatives Affect the Inhibition Ability of EGFR
E J; Liu Y; Guan S; Luo Z; Han F; Han W; Wang S; Zhang H
Molecules; 2020 Feb; 25(4):. PubMed ID: 32085409
[TBL] [Abstract][Full Text] [Related]
82. Design, Synthesis, and Biological Evaluation of Pyrimido[4,5- d]pyrimidine-2,4(1 H,3 H)-diones as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation.
Hao Y; Lyu J; Qu R; Tong Y; Sun D; Feng F; Tong L; Yang T; Zhao Z; Zhu L; Ding J; Xu Y; Xie H; Li H
J Med Chem; 2018 Jul; 61(13):5609-5622. PubMed ID: 29906114
[TBL] [Abstract][Full Text] [Related]
83. [TKI Resistance for T790M Mutation].
Wang H; Guo R; Zhang L
Zhongguo Fei Ai Za Zhi; 2015 Apr; 18(4):245-50. PubMed ID: 25936890
[TBL] [Abstract][Full Text] [Related]
84. Identification of small-molecule EGFR allosteric inhibitors by high-throughput docking.
Caporuscio F; Tinivella A; Restelli V; Semrau MS; Pinzi L; Storici P; Broggini M; Rastelli G
Future Med Chem; 2018 Jul; 10(13):1545-1553. PubMed ID: 29766737
[TBL] [Abstract][Full Text] [Related]
85. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors.
Gazdar AF
Oncogene; 2009 Aug; 28 Suppl 1(Suppl 1):S24-31. PubMed ID: 19680293
[TBL] [Abstract][Full Text] [Related]
86. Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein.
Aertgeerts K; Skene R; Yano J; Sang BC; Zou H; Snell G; Jennings A; Iwamoto K; Habuka N; Hirokawa A; Ishikawa T; Tanaka T; Miki H; Ohta Y; Sogabe S
J Biol Chem; 2011 May; 286(21):18756-65. PubMed ID: 21454582
[TBL] [Abstract][Full Text] [Related]
87. Untangling Dual-Targeting Therapeutic Mechanism of Epidermal Growth Factor Receptor (EGFR) Based on Reversed Allosteric Communication.
Qiu Y; Yin X; Li X; Wang Y; Fu Q; Huang R; Lu S
Pharmaceutics; 2021 May; 13(5):. PubMed ID: 34070173
[TBL] [Abstract][Full Text] [Related]
88. Structure-based virtual screening and molecular dynamics simulations for detecting novel candidates for allosteric inhibition of EGFRT790M.
Çoban G
J Biomol Struct Dyn; 2024; 42(2):571-597. PubMed ID: 37029759
[TBL] [Abstract][Full Text] [Related]
89. Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations.
Littlefield P; Liu L; Mysore V; Shan Y; Shaw DE; Jura N
Sci Signal; 2014 Dec; 7(354):ra114. PubMed ID: 25468994
[TBL] [Abstract][Full Text] [Related]
90. Mechanistic Modeling of Lys745 Sulfonylation in EGFR C797S Reveals Chemical Determinants for Inhibitor Activity and Discriminates Reversible from Irreversible Agents.
Arafet K; Scalvini L; Galvani F; Martí S; Moliner V; Mor M; Lodola A
J Chem Inf Model; 2023 Feb; 63(4):1301-1312. PubMed ID: 36762429
[TBL] [Abstract][Full Text] [Related]
91. Insights into the negative regulation of EGFR upon the binding of an allosteric inhibitor.
Li M; Xu Y; Guo J
Chem Biol Drug Des; 2022 Apr; 99(4):650-661. PubMed ID: 35152550
[TBL] [Abstract][Full Text] [Related]
92. Reckoning apigenin and kaempferol as a potential multi-targeted inhibitor of EGFR/HER2-MEK pathway of metastatic colorectal cancer identified using rigorous computational workflow.
Sharma A; Sinha S; Rathaur P; Vora J; Jha PC; Johar K; Rawal RM; Shrivastava N
Mol Divers; 2022 Dec; 26(6):3337-3356. PubMed ID: 35147860
[TBL] [Abstract][Full Text] [Related]
93. Harnessing the druggability at orthosteric and allosteric sites of PD-1 for small molecule discovery by an integrated in silico pipeline.
Mittal L; Tonk RK; Awasthi A; Asthana S
Comput Biol Chem; 2023 Dec; 107():107965. PubMed ID: 37826990
[TBL] [Abstract][Full Text] [Related]
94. Inhibition of a lower potency target drives the anticancer activity of a clinical p38 inhibitor.
Bhattacharjee D; Bakar J; Chitnis SP; Sausville EL; Ashtekar KD; Mendelson BE; Long K; Smith JC; Heppner DE; Sheltzer JM
Cell Chem Biol; 2023 Oct; 30(10):1211-1222.e5. PubMed ID: 37827156
[TBL] [Abstract][Full Text] [Related]
95. Identification of novel allosteric binding sites and multi-targeted allosteric inhibitors of receptor and non-receptor tyrosine kinases using a computational approach.
Kakarala KK; Jamil K
J Biomol Struct Dyn; 2022 Sep; 40(15):6889-6909. PubMed ID: 33682622
[TBL] [Abstract][Full Text] [Related]
96. Validation of an Allosteric Binding Site of Src Kinase Identified by Unbiased Ligand Binding Simulations.
Mingione VR; Foda ZH; Paung Y; Philipose H; Rangwala AM; Shan Y; Seeliger MA
J Mol Biol; 2022 Sep; 434(17):167628. PubMed ID: 35595169
[TBL] [Abstract][Full Text] [Related]
97. Targeting EGFR allosteric site with marine-natural products of
Nurisyah ; Ramadhan DSF; Dewi R; Asikin A; Daswi DR; Adam A; Chaerunnimah ; Sunarto ; Rafika ; Artati ; Fakih TM
Curr Res Struct Biol; 2024; 7():100125. PubMed ID: 38282755
[TBL] [Abstract][Full Text] [Related]
98. A biophysical framework for double-drugging kinases.
Kim C; Ludewig H; Hadzipasic A; Kutter S; Nguyen V; Kern D
Proc Natl Acad Sci U S A; 2023 Aug; 120(34):e2304611120. PubMed ID: 37590418
[TBL] [Abstract][Full Text] [Related]
99. High-throughput computational screening and
Shahrani MA; Gahtani R; Abohassan M; Alshahrani M; Alraey Y; Dera A; Asiri MR; Rajagopalan P
Oncol Res; 2023; 32(2):251-259. PubMed ID: 38186572
[TBL] [Abstract][Full Text] [Related]
100. Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors.
Heppner D; Wittlinger F; Ogboo B; Shevchenko E; Damghani T; Pham C; Schaeffner I; Oligny B; Chitnis S; Beyett T; Rasch A; Buckley B; Urul D; Shaurova T; May E; Schaefer E; Eck M; Hershberger P; Poso A; Laufer S
Res Sq; 2023 Sep; ():. PubMed ID: 37790373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
